Home/Filings/4/0001012975-19-000242
4//SEC Filing

ARCH Venture Fund VII, L.P. 4

Accession 0001012975-19-000242

CIK 0001556263other

Filed

Mar 13, 8:00 PM ET

Accepted

Mar 14, 6:57 PM ET

Size

19.1 KB

Accession

0001012975-19-000242

Insider Transaction Report

Form 4
Period: 2019-03-12
Transactions
  • Sale

    Common Stock

    2019-03-12$7.37/sh40,092$295,3744,432,462 total
  • Sale

    Common Stock

    2019-03-13$8.20/sh2,820$23,1224,348,051 total
  • Sale

    Common Stock

    2019-03-14$8.15/sh43,000$350,4414,305,051 total
  • Sale

    Common Stock

    2019-03-13$7.89/sh81,591$643,4434,350,871 total
Footnotes (6)
  • [F1]Reflects aggregation of stock sales within the range of $7.27 to $7.51. ARCH Venture Fund VII, L.P. ("ARCH Fund VII") can provide detailed support upon request.
  • [F2]Reflects aggregation of stock sales within the range of $7.19 to $8.185. ARCH Fund VII can provide detailed support upon request.
  • [F3]Reflects aggregation of stock sales within the range of $8.19 to $8.22. ARCH Fund VII can provide detailed support upon request.
  • [F4]Reflects aggregation of stock sales within the range of $7.915 to $8.39. ARCH Fund VII can provide detailed support upon request.
  • [F5]Beneficial ownership consists of 4,305,051 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
  • [F6]The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Issuer

Syros Pharmaceuticals, Inc.

CIK 0001556263

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001402439

Filing Metadata

Form type
4
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 6:57 PM ET
Size
19.1 KB